Jupiter Topco LLC Takes Position in AtriCure, Inc. $ATRC

Jupiter Topco LLC purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,883 shares of the medical device company’s stock, valued at approximately $640,000.

Several other large investors also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure in the 2nd quarter valued at about $37,000. Smartleaf Asset Management LLC raised its stake in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares in the last quarter. Harbor Investment Advisory LLC acquired a new stake in shares of AtriCure during the 2nd quarter valued at about $40,000. Allworth Financial LP acquired a new position in AtriCure in the second quarter worth approximately $43,000. Finally, Fifth Third Bancorp bought a new stake in AtriCure in the first quarter worth approximately $51,000. 99.11% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at AtriCure

In related news, insider Karl Dahlquist sold 9,370 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Salvatore Privitera sold 7,763 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $52.50, for a total value of $407,557.50. Following the transaction, the insider directly owned 150,921 shares in the company, valued at approximately $7,923,352.50. This represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 61,379 shares of company stock worth $2,557,552. Corporate insiders own 4.00% of the company’s stock.

AtriCure Stock Performance

NASDAQ ATRC opened at $51.52 on Monday. The company’s fifty day moving average is $40.10 and its two-hundred day moving average is $32.83. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $53.50. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of 245.35 and a beta of 1.26.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter last year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. UBS Group decreased their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, BTIG Research lifted their price target on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.